SARS coronavirus 2: from genome to infectome

Respiratory Research

Table 4 List of therapeutic candidates against COVID-19

S. no	Drug name	Clinical trial	Trial	Treatment	References
1.	Pacritinib	Phase 3	NCT04404361	Kinase inhibitor	[170]
2.	Enoxaparin	Phase 3	NCT04401293	Antithrombotic	[171]
3.	Remdesivir + Baricitinib	Phase 3	NCT04401579	Antiviral	[172]
4.	Remdesivir	Phase 3	NCT04401579	Antiviral	[172]
5.	Hydroxychloroquine	Phase 3	NCT04410562	Antimalarial	[173]
6.	Favipiravir + Hydroxychloroquine	Phase 3	NCT04411433	Antiviral	[174, 175]
7.	ASC09 + Oseltamivir	Phase 3	NCT04261270	Antiviral	[176]
8.	ASC09 + Ritonavir	NA	NCT04261907	Antiviral	[176]
9.	Tocilizumab (IL-6)	Phase 3	NCT04412772	Monoclonal antibodies	[177]
10.	Anakinra	Phase 3	NCT04412291	Anti-inflammatory	[178]
11.	Ivermectin	Completed	NCT04422561	Antiparasitic	[179]
12.	Budesonide dry powder inhaler	Phase 2	NCT04416399	Corticosteroid	[180]
13.	LY3819253	Phase 3	NCT04427501	Corticosteroid	[181]
14.	Atazanavir and dexamethasone	Phase 3	NCT04452565	Corticosteroid and antiviral	[182]
15.	Colchicine	Phase 2	NCT04326790	Anti-inflammatory	[183]
16.	Corticosteroid	Phase 3	NCT04381936	Corticosteroid	[184]
17.	Azithromycin	Phase 3	NCT04381936	Antibacterial	[184]
18.	Convalescent plasma	Phase 3	NCT04425915	Convalescent plasma	[130]
19.	NA-831 and dexamethasone	Phase 3	NCT04452565	Corticosteroid	[182]
20.	Camostat Mesilate	Phase 2	NCT04470544	Protease inhibitor	[81]

ISSN: 1465-993X